

May. 11, 2012

**NinePoint Medical to Unveil NvisionVLE Imaging System at DDW 2012**


**Cambridge, Mass. – May 11, 2012** – NinePoint Medical, Inc., an emerging leader in the development of medical devices for in vivo pathology, today announced that the company will preview its next-generation optical imaging technology, the NvisionVLE™ Imaging System, at Digestive Disease Week 2012 (DDW 2012), being held May 19 to 22 at the San Diego Convention Center in San Diego. NinePoint Medical will provide public demonstrations of the NvisionVLE Imaging System, which is designed to bridge the gap between diagnosis and disease treatment by enabling physicians and pathologists to evaluate high-resolution, volumetric images of organs and tissues in real time.

“We are looking forward to providing DDW 2012 attendees with informative and interactive demonstrations of our proprietary NvisionVLE Imaging System,” said Charles Carignan, M.D., president and chief executive officer of NinePoint Medical. “The NvisionVLE Imaging System is designed to provide real-time images that will enable physicians to visually assess diseased tissues deeper than is possible with endoscopy, the current standard of care. We’re continuing to make important progress and this has been an exciting year for us, with 510(k) clearance from the FDA and the initiation of our multi-center clinical trial for the evaluation of Barrett’s esophagus.”

The NvisionVLE Imaging System is the first volumetric, optical coherence tomography (OCT) device cleared by the U.S. Food and Drug Administration (FDA) for endoscopic imaging that generates cross sectional and longitudinal images simultaneously, in real time. Unlike traditional imaging devices that image only the surface of organs and tissues, NinePoint Medical’s proprietary technology enables the generation of images up to 3mm deep and at better than 10-micron resolution.

NinePoint Medical recently initiated a clinical trial to evaluate high-resolution optical imaging of Barrett’s esophagus using the NvisionVLE Imaging System. Barrett’s esophagus is one of the most common precursors to esophageal cancer, which is ranked among the top 10 causes of cancer-related deaths worldwide. In addition, in January 2012 the company announced 510(k) clearance from the FDA to market its NvisionVLE Imaging System for use as an imaging tool in the evaluation of human tissue microstructure by providing two-dimensional, cross sectional, real-time depth visualization. Based on the rapid and significant progress made in the development of the NvisionVLE Imaging System this year, NinePoint Medical remains on track for a commercial launch of the System in 2013.

For a demo of the NvisionVLE Imaging System at DDW 2012, please visit NinePoint Medical at booth 925.



### **About Digestive Diseases Week 2012**

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 19 - 22, 2012, at the San Diego Convention Center. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit [www.ddw.org](http://www.ddw.org).

### **About NinePoint Medical, Inc.**

NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices focused on dramatically improving patient care. Through its proprietary NvisionVLE™ Imaging System, NinePoint intends to bridge the gap between the diagnosis and treatment of disease. The NvisionVLE Imaging System will enable physicians and pathologists, for the first time, to view real-time, high-resolution, volumetric images of organs and tissues up to 3mm deep at better than 10 micron resolution. Initially, NinePoint is focusing on devices that enable real-time, endoscopic screening and surveillance of diseases of the mucosa of various tissues that are often precancerous. Eventually, the company intends to develop medical devices that provide physicians with immediately actionable information, which will allow them to diagnose and treat patients during the same procedure. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the health care system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. For more information, please visit [www.ninepointmedical.com](http://www.ninepointmedical.com).